BR112021018528A2 - Uso de moduladores do receptor gabaa para tratamento de dor - Google Patents

Uso de moduladores do receptor gabaa para tratamento de dor

Info

Publication number
BR112021018528A2
BR112021018528A2 BR112021018528A BR112021018528A BR112021018528A2 BR 112021018528 A2 BR112021018528 A2 BR 112021018528A2 BR 112021018528 A BR112021018528 A BR 112021018528A BR 112021018528 A BR112021018528 A BR 112021018528A BR 112021018528 A2 BR112021018528 A2 BR 112021018528A2
Authority
BR
Brazil
Prior art keywords
receptor modulators
gabaa receptor
pain management
pain
disclosed
Prior art date
Application number
BR112021018528A
Other languages
English (en)
Inventor
Jed Hubbs
Matthew Toczko
Original Assignee
Neurocycle Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocycle Therapeutics Inc filed Critical Neurocycle Therapeutics Inc
Publication of BR112021018528A2 publication Critical patent/BR112021018528A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

uso de moduladores do receptor gabaa para tratamento de dor. são divulgados nesse documento moduladores do receptor gabaa e composições compreendendo moduladores do receptor gabaa para o tratamento da dor e condições associadas, tal como fibromialgia. também são divulgados nesse documento métodos de tratamento da dor e condições associadas em um indivíduo por meio da administração de moduladores do receptor gabaa ou composição como descrita nesse documento.
BR112021018528A 2019-03-18 2020-03-18 Uso de moduladores do receptor gabaa para tratamento de dor BR112021018528A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962819794P 2019-03-18 2019-03-18
PCT/US2020/023355 WO2020191047A1 (en) 2019-03-18 2020-03-18 Use of gabaa receptor modulators for treatment of pain

Publications (1)

Publication Number Publication Date
BR112021018528A2 true BR112021018528A2 (pt) 2022-02-08

Family

ID=72521189

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018528A BR112021018528A2 (pt) 2019-03-18 2020-03-18 Uso de moduladores do receptor gabaa para tratamento de dor

Country Status (12)

Country Link
US (1) US20220152037A1 (pt)
EP (1) EP3937946A4 (pt)
JP (1) JP7323631B2 (pt)
KR (1) KR20220006508A (pt)
CN (1) CN113840610A (pt)
AU (1) AU2020241731B2 (pt)
BR (1) BR112021018528A2 (pt)
CA (1) CA3132810A1 (pt)
IL (1) IL286396A (pt)
MX (1) MX2021011263A (pt)
SG (1) SG11202109526PA (pt)
WO (1) WO2020191047A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023101899A1 (en) * 2021-11-30 2023-06-08 The Regents Of The University Of California Compositions and methods for ameliorating sjogren's syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117277D0 (en) * 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
AU783516B2 (en) * 2001-04-30 2005-11-03 Warner-Lambert Company Methods, kits and compositions for using pyrrole derivatives
US8835424B2 (en) * 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US7855196B2 (en) * 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
JP5183808B2 (ja) * 2008-08-29 2013-04-17 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロ−ピリダジン誘導体
US20110082147A1 (en) * 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
EP3064208A1 (en) * 2015-03-02 2016-09-07 Les Hôpitaux Universitaires de Genève Use of n-desmethylclobazam in the treatment of chronic pain disorders and related methods
CA2979701C (en) * 2015-03-20 2023-01-03 Uwm Research Foundation, Inc. Oxazole substituted benzimidazodiazepines and their uses as gabaergic ligands
MX2018009252A (es) * 2016-01-27 2019-01-21 Univ Zuerich Uso de moduladores de receptores de gabaa para el tratamiento de picor.
DK3439665T3 (da) * 2016-03-18 2022-09-26 Uwm Res Foundation Inc Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister
AU2019255282B2 (en) * 2018-04-18 2024-08-08 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds, methods of making, and uses thereof

Also Published As

Publication number Publication date
CA3132810A1 (en) 2020-09-24
US20220152037A1 (en) 2022-05-19
EP3937946A1 (en) 2022-01-19
JP7323631B2 (ja) 2023-08-08
KR20220006508A (ko) 2022-01-17
SG11202109526PA (en) 2021-10-28
AU2020241731A1 (en) 2021-09-30
AU2020241731B2 (en) 2023-09-07
JP2022525539A (ja) 2022-05-17
CN113840610A (zh) 2021-12-24
MX2021011263A (es) 2021-10-01
EP3937946A4 (en) 2022-05-11
WO2020191047A1 (en) 2020-09-24
IL286396A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
BR112022017393A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
BR112017007767A2 (pt) canabidiol para uso, método para tratar um paciente que sofre de complexo esclerose tuberosa, e, composição.
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
BR112018004680A2 (pt) método de tratamento de distúrbios de desenvolvimento
BR112019000692A8 (pt) Moduladores de somatostatina e usos destes
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
BR112017001162A2 (pt) métodos para tratar paramixovírus
BR112016022742A2 (pt) composições e métodos para modular a expressão de receptor de hormônio do crescimento
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
MX2020005547A (es) Moduladores de la actividad del complemento.
DOP2021000044A (es) Moduladores de la expresión de pnpla3
BR112019024566A2 (pt) inibidores de pirazol magl
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112017017970A2 (pt) composição de fragrância e combinação de fragrâncias
BR112021024634A2 (pt) Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
BR112022006016A2 (pt) Métodos e materiais para tratar neurotoxicidade
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
BR112016000338A8 (pt) composto enriquecido em deutério de fórmula estrutural i, composição farmacêutica, e usos de um composto
BR112019003816A2 (pt) composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição
BR112021014566A2 (pt) Moduladores de gpr35